• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Acentra Health Appoints Ezmeralda Sager as Chief Transformation Officer

    1/23/25 9:42:00 AM ET
    $CG
    Investment Managers
    Finance
    Get the next $CG alert in real time by email

    MCLEAN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, announced it has appointed Ezmeralda Sager as Executive Vice President and Chief Transformation Officer (CTO), effective January 6, 2025.

    In this role, Sager will spearhead enterprise-wide change initiatives to help Acentra Health build upon its strong track record of innovation and execution for its clients. She will provide strategic guidance on process improvements to optimize the development and delivery of the company's products, solutions, and services to its state, federal, and commercial healthcare clients. As a member of the Executive Leadership Team, Sager will lead a Transformation Office and work with senior leaders to drive business process changes that strengthen the company's organizational effectiveness and further differentiate its reputation as a market leader.

    "Acentra Health has always been a leader in pushing the boundaries of possibility, from delivering the first Medicaid Enterprise System in the cloud to creating one of the first clinical GenAI solutions to be reviewed and approved by the Centers for Medicare and Medicaid Services (CMS)," said Todd Stottlemyer, Acentra Health CEO. "We have made great strides in transformation, through automation, AI, and machine learning, and Ezmeralda's leadership will be pivotal in accelerating our capacity to deliver exceptional value and outcomes for our clients."

    Prior to joining Acentra Health, Sager served as Vice President of Global Transformation at Johnson Controls, Inc., where she led the transformation portfolio for the $27 billion annual revenue company focused on smart, healthy, and sustainable building solutions. She also held senior leadership roles at Booz Allen Hamilton, overseeing enterprise strategy and transformation initiatives, and at SAIC, where she managed the organizational effectiveness practice. Across her 20-plus year career, Sager has established herself as a disruptive force for change, bringing clarity and focus to complex programs to deliver measurable results.

    "Transformation is a cornerstone for organizations striving to achieve sustainable growth and continual advancement," said Sager. "As healthcare becomes increasingly complex, the ability to innovate, streamline operations, and deliver measurable outcomes is more critical than ever. I am pleased to join Acentra Health at such a vital point in its growth journey and look forward to building on the company's success to create lasting value for our clients and those they serve."

    Founded in 2023, Acentra Health was named by Washington Business Journal as one of the Washington, D.C., area's "Fastest Growing Companies" for 2024. That same year, the Association of Corporate Growth's (ACG) National Capital Chapter named the company a Corporate Growth Award winner for creating significant corporate value in 2023.

    About Acentra Health

    Acentra Health combines public sector knowledge, clinical expertise, and technological ingenuity to modernize the healthcare experience for state, federal, and commercial partners, and their priority populations. From designing and developing advanced claims, encounter, and provider solutions that drive efficiency and cost savings to delivering clinically focused service models for care management, clinical assessments, and quality oversight, Acentra Health is accelerating better health outcomes. Acentra Health is backed by Carlyle (NASDAQ:CG), a global investment firm. Learn more at acentra.com.

    Media Contact:

    Janice Moore

    Vice President, Corporate Communications

    703-214-3552

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9691f2de-1e12-44ed-9f8e-aa032eff60ee



    Primary Logo

    Get the next $CG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CG

    DatePrice TargetRatingAnalyst
    5/14/2025$56.00Hold → Buy
    TD Cowen
    3/19/2025Outperform → Perform
    Oppenheimer
    1/3/2025$60.00Peer Perform → Outperform
    Wolfe Research
    9/12/2024$42.00Equal Weight
    Wells Fargo
    8/27/2024$55.00Buy
    Redburn Atlantic
    8/6/2024$46.00 → $44.00Overweight → Neutral
    JP Morgan
    1/19/2024$40.00 → $41.00Buy → Neutral
    Citigroup
    1/4/2024$42.00Market Perform
    TD Cowen
    More analyst ratings

    $CG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Diversified Energy and Carlyle Enter Strategic Partnership to Invest in Up to $2 Billion of PDP Energy Assets

      BIRMINGHAM, Ala. and NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Diversified Energy Company PLC ((LSE: DEC, NYSE:DEC) ("Diversified," or "DEC"), a leading publicly traded natural gas and liquids production company, and global investment firm Carlyle (NASDAQ:CG) have today announced a strategic partnership to invest in up to $2 billion in existing proved developed producing (PDP) natural gas and oil assets across the United States. This exclusive partnership will combine Carlyle's deep credit and structuring expertise, led by Carlyle's asset-backed finance (ABF) team, with Diversified's market-leading operating capabilities and differentiated business model of acquiring and optimizing port

      6/23/25 4:31:00 PM ET
      $CG
      $DEC
      Investment Managers
      Finance
    • Trucordia to Receive $1.3 Billion Strategic Investment from Carlyle

      Transaction positions company for accelerated growth through improved capital structure and simplified governance LINDON, Utah and NEW YORK, June 4, 2025 /PRNewswire/ -- Trucordia today announced it will receive a $1.3 billion strategic investment from global investment firm Carlyle's Global Credit platform. The transaction will reduce Trucordia's leverage and simplify its governance structure by repurchasing units from existing minority investors. The transaction, which is expected to close this month and values Trucordia at $5.7 billion, provides the company with long-term

      6/4/25 7:00:00 AM ET
      $CG
      Investment Managers
      Finance
    • bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

      New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ:BLUE) ("bluebird"), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ:CG) and SK Capital Partners, LP ("SK Capital"). With the closing of the transaction, bluebird's common stock has ceased trading and will no longer

      6/2/25 8:34:00 AM ET
      $BLUE
      $CG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Investment Managers
      Finance

    $CG
    SEC Filings

    See more
    • The Carlyle Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders

      8-K - Carlyle Group Inc. (0001527166) (Filer)

      5/30/25 5:19:46 PM ET
      $CG
      Investment Managers
      Finance
    • Amendment: SEC Form SCHEDULE 13G/A filed by The Carlyle Group Inc.

      SCHEDULE 13G/A - Carlyle Group Inc. (0001527166) (Subject)

      5/13/25 11:44:13 AM ET
      $CG
      Investment Managers
      Finance
    • SEC Form 13F-HR filed by The Carlyle Group Inc.

      13F-HR - Carlyle Group Inc. (0001527166) (Filer)

      5/9/25 4:37:58 PM ET
      $CG
      Investment Managers
      Finance